[Therapy of tic disorders].
Tremendous progress has taken place in the last 8 years since the publication of our review on «Therapy of Tic Disorders» in the Zeitschrift für Kinder- und Jugendpsychiatrie. Several steps in treatment have been specified. For example, consensus-based indications for treatment have been published, and a detailed manual for a so-called habit-reversal training program has been developed and evaluated. In addition, new treatment options such as aripiprazole and deep-brain stimulation have been implemented. Increasing attention is being given to the disabling consequences of the commonly co-occurring psychiatric conditions known as ADHD or OCD. Nevertheless, there is still much to be learned about the treatment of tic disorders; standardized and sufficiently large drug trials in patients with tic disorders fulfilling evidence-based medicine standards are still scarce. The same is true for direct comparisons of different agents as well as of medication versus behavioral treatment. Finally, the question of how to predict the individual course of tics and how best to deal with the problems of waxing and waning of tics in this context still limits evidence base for treatment decisions. Large clinical experience is still a pre-requisite for making optimal decisions for the treatment of individual patients suffering from a tic disorder.
Kinder- und Jugendpsychiatrie und Psychotherapie, Universität Dresden. veit.roessner@uniklinikum-dresden.de
Veit
V
Roessner
Katia
K
Schoenefeld
Judith
J
Buse
Sina
S
Wanderer
Aribert
A
Rothenberger
D000322:Adrenergic Agonists / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000523:psychology / Q000628:therapy; D001521:Behavior Therapy; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D015897:Comorbidity; D003663:Decision Trees; D046690:Deep Brain Stimulation; D015259:Dopamine Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000175:diagnosis / Q000523:psychology / Q000628:therapy; D012934:Social Isolation; D057545:Social Stigma; D013981:Tic Disorders / Q000175:diagnosis / Q000523:psychology / Q000628:therapy*; D005879:Tourette Syndrome / Q000175:diagnosis / Q000523:psychology / Q000628:therapy*
D000322:Adrenergic Agonists; D014150:Antipsychotic Agents; D001549:Benzamides; D015259:Dopamine Agents